New generation calcium channel blockers in hypertensive treatment

Yuri Ozawa, Koichi Hayashi, Hiroyuki Kobori

研究成果: Article

6 引用 (Scopus)

抄録

During a couple of decades, a number of antihypertensive drugs have been developed, and the choice of hypertension treatment has been expanded. Among antihypertensive drugs, calcium channel blockers, which inhibit L-type voltage-gated calcium channels, are potent vasodilators, and have been used as a first- or second-line drug. Dihydropyridine-class calcium channel blockers are categorized into three generations according to the length of activity, and long-acting calcium channel blockers cause less activation of sympathetic nervous system, and are reported to offer beneficial action compared with short-action agents. Furthermore, novel types of calcium channel blockers have been developed that possess the blocking action on other calcium channel subtypes (T- and N-type), and exert agent-specific action apart from their class effects, such as the effects on heart rate and renin/aldosterone release. These additional benefits conferred by T/N-type calcium channel blockade are anticipated to provide organ protective actions in the treatment of hypertension, in addition to the blood pressure-lowering effect of L-type calcium channel blockade. In conclusion, novel calcium channel blockers with sustained activity and T/N-type calcium channel blocking action could provide more beneficial effects than classical blockers, and may expand the clinical utility of these agents.

元の言語English
ページ(範囲)103-111
ページ数9
ジャーナルCurrent Hypertension Reviews
2
発行部数2
DOI
出版物ステータスPublished - 2006 5

Fingerprint

Calcium Channel Blockers
T-Type Calcium Channels
N-Type Calcium Channels
Calcium Channels
Antihypertensive Agents
Hypertension
L-Type Calcium Channels
Sympathetic Nervous System
Aldosterone
Vasodilator Agents
Renin
Heart Rate
Blood Pressure
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Internal Medicine

これを引用

New generation calcium channel blockers in hypertensive treatment. / Ozawa, Yuri; Hayashi, Koichi; Kobori, Hiroyuki.

:: Current Hypertension Reviews, 巻 2, 番号 2, 05.2006, p. 103-111.

研究成果: Article

Ozawa, Yuri ; Hayashi, Koichi ; Kobori, Hiroyuki. / New generation calcium channel blockers in hypertensive treatment. :: Current Hypertension Reviews. 2006 ; 巻 2, 番号 2. pp. 103-111.
@article{10cba53019e34d2babca65a47eae85de,
title = "New generation calcium channel blockers in hypertensive treatment",
abstract = "During a couple of decades, a number of antihypertensive drugs have been developed, and the choice of hypertension treatment has been expanded. Among antihypertensive drugs, calcium channel blockers, which inhibit L-type voltage-gated calcium channels, are potent vasodilators, and have been used as a first- or second-line drug. Dihydropyridine-class calcium channel blockers are categorized into three generations according to the length of activity, and long-acting calcium channel blockers cause less activation of sympathetic nervous system, and are reported to offer beneficial action compared with short-action agents. Furthermore, novel types of calcium channel blockers have been developed that possess the blocking action on other calcium channel subtypes (T- and N-type), and exert agent-specific action apart from their class effects, such as the effects on heart rate and renin/aldosterone release. These additional benefits conferred by T/N-type calcium channel blockade are anticipated to provide organ protective actions in the treatment of hypertension, in addition to the blood pressure-lowering effect of L-type calcium channel blockade. In conclusion, novel calcium channel blockers with sustained activity and T/N-type calcium channel blocking action could provide more beneficial effects than classical blockers, and may expand the clinical utility of these agents.",
keywords = "Heart failure, N-type calcium channels, Renal protection, T-type calcium channels, Tachycardia",
author = "Yuri Ozawa and Koichi Hayashi and Hiroyuki Kobori",
year = "2006",
month = "5",
doi = "10.2174/157340206776877370",
language = "English",
volume = "2",
pages = "103--111",
journal = "Current Medical Imaging Reviews",
issn = "1573-4056",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - New generation calcium channel blockers in hypertensive treatment

AU - Ozawa, Yuri

AU - Hayashi, Koichi

AU - Kobori, Hiroyuki

PY - 2006/5

Y1 - 2006/5

N2 - During a couple of decades, a number of antihypertensive drugs have been developed, and the choice of hypertension treatment has been expanded. Among antihypertensive drugs, calcium channel blockers, which inhibit L-type voltage-gated calcium channels, are potent vasodilators, and have been used as a first- or second-line drug. Dihydropyridine-class calcium channel blockers are categorized into three generations according to the length of activity, and long-acting calcium channel blockers cause less activation of sympathetic nervous system, and are reported to offer beneficial action compared with short-action agents. Furthermore, novel types of calcium channel blockers have been developed that possess the blocking action on other calcium channel subtypes (T- and N-type), and exert agent-specific action apart from their class effects, such as the effects on heart rate and renin/aldosterone release. These additional benefits conferred by T/N-type calcium channel blockade are anticipated to provide organ protective actions in the treatment of hypertension, in addition to the blood pressure-lowering effect of L-type calcium channel blockade. In conclusion, novel calcium channel blockers with sustained activity and T/N-type calcium channel blocking action could provide more beneficial effects than classical blockers, and may expand the clinical utility of these agents.

AB - During a couple of decades, a number of antihypertensive drugs have been developed, and the choice of hypertension treatment has been expanded. Among antihypertensive drugs, calcium channel blockers, which inhibit L-type voltage-gated calcium channels, are potent vasodilators, and have been used as a first- or second-line drug. Dihydropyridine-class calcium channel blockers are categorized into three generations according to the length of activity, and long-acting calcium channel blockers cause less activation of sympathetic nervous system, and are reported to offer beneficial action compared with short-action agents. Furthermore, novel types of calcium channel blockers have been developed that possess the blocking action on other calcium channel subtypes (T- and N-type), and exert agent-specific action apart from their class effects, such as the effects on heart rate and renin/aldosterone release. These additional benefits conferred by T/N-type calcium channel blockade are anticipated to provide organ protective actions in the treatment of hypertension, in addition to the blood pressure-lowering effect of L-type calcium channel blockade. In conclusion, novel calcium channel blockers with sustained activity and T/N-type calcium channel blocking action could provide more beneficial effects than classical blockers, and may expand the clinical utility of these agents.

KW - Heart failure

KW - N-type calcium channels

KW - Renal protection

KW - T-type calcium channels

KW - Tachycardia

UR - http://www.scopus.com/inward/record.url?scp=33746109293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746109293&partnerID=8YFLogxK

U2 - 10.2174/157340206776877370

DO - 10.2174/157340206776877370

M3 - Article

AN - SCOPUS:33746109293

VL - 2

SP - 103

EP - 111

JO - Current Medical Imaging Reviews

JF - Current Medical Imaging Reviews

SN - 1573-4056

IS - 2

ER -